BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Haefner M, Bluethner T, Niederhagen M, Moebius C, Wittekind C, Mossner J, Caca K, Wiedmann M. Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors. World J Gastroenterol 2008; 14(23): 3681-3692 [PMID: 18595135 DOI: 10.3748/wjg.14.3681]
URL: https://www.wjgnet.com/1007-9327/full/v14/i23/3681.htm
Number Citing Articles
1
Maria Graziella Catalano, Mariateresa Pugliese, Eleonora Gargantini, Cristina Grange, Benedetta Bussolati, Sofia Asioli, Ornella Bosco, Roberta Poli, Alessandra Compagnone, Andrea Bandino, Franco Mainini, Nicoletta Fortunati, Giuseppe Boccuzzi. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivoInternational Journal of Cancer 2012; 130(3): 694 doi: 10.1002/ijc.26057
2
Yudibeth Sixto-López, Martiniano Bello, José Correa-Basurto. Insights into structural features of HDAC1 and its selectivity inhibition elucidated by Molecular dynamic simulation and Molecular DockingJournal of Biomolecular Structure and Dynamics 2019; 37(3): 584 doi: 10.1080/07391102.2018.1441072
3
Dmitriy I Dovzhanskiy, Stefanie M Arnold, Thilo Hackert, Ina Oehme, Olaf Witt, Klaus Felix, Nathalia Giese, Jens Werner. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancerBMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-226
4
Lubna Wasim, Madhu Chopra. Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cellsBiomedicine & Pharmacotherapy 2016; 84: 1393 doi: 10.1016/j.biopha.2016.10.057
5
Elisabeth Hessmann, Steven A Johnsen, Jens T Siveke, Volker Ellenrieder. Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?Gut 2017; 66(1): 168 doi: 10.1136/gutjnl-2016-312539
6
Günter Schneider, Oliver H. Krämer, Petra Fritsche, Susanne Schüler, Roland M. Schmid, Dieter Saur. Targeting histone deacetylases in pancreatic ductal adenocarcinomaJournal of Cellular and Molecular Medicine 2010; 14(6a): 1255 doi: 10.1111/j.1582-4934.2009.00974.x
7
Ouaïssi Mehdi, Silvy Françoise, Costa Lima Sofia, Giger Urs, Zemmour Kevin, Sastre Bernard, Sielezneff Igor, Cordeiro-da-Silva Anabela, Lombardo Dominique, Mas Eric, Ouaïssi Ali. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA)Pancreatology 2012; 12(2): 146 doi: 10.1016/j.pan.2012.02.013
8
Weiqiang Zhou, I-Chau Liang, Nelson S. Yee. Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancerCancer Biology & Therapy 2011; 11(7): 659 doi: 10.4161/cbt.11.7.14720
9
Jiahuai Tan, Shundong Cang, Yuehua Ma, Richard L Petrillo, Delong Liu. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsJournal of Hematology & Oncology 2010; 3(1) doi: 10.1186/1756-8722-3-5
10
Ahmed Abdullah Ahmed, Stephen Neidle. A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer CellsMolecules 2020; 25(22): 5407 doi: 10.3390/molecules25225407
11
Georg Feldmann, Anirban Maitra. Drug Discovery in Pancreatic Cancer2010; : 181 doi: 10.1007/978-1-4419-1160-5_10
12
Avineesh Singh, Vijay K. Patel, Deepak K. Jain, Preeti Patel, Harish Rajak. Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future ProspectsOncology and Therapy 2016; 4(1): 73 doi: 10.1007/s40487-016-0023-1
13
Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, Serena Valsami, Dimitrios Dimitroulis. Pharmacoepigenetics2019; : 501 doi: 10.1016/B978-0-12-813939-4.00013-9
14
M. Cecilia Crisanti, Africa F. Wallace, Veena Kapoor, Fabian Vandermeers, Melissa L. Dowling, Luana P. Pereira, Kara Coleman, Barbara G. Campling, Zvi G. Fridlender, Gary D. Kao, Steven M. Albelda. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cellsin vitroandin vivowith particular efficacy for small cell lung cancerMolecular Cancer Therapeutics 2009; 8(8): 2221 doi: 10.1158/1535-7163.MCT-09-0138
15
Yi Zou, Gillian M. Howell, Lisa E. Humphrey, Jing Wang, Michael G. Brattain, Lu-Zhe Sun. Ron Knockdown and Ron Monoclonal Antibody IMC-RON8 Sensitize Pancreatic Cancer to Histone Deacetylase Inhibitors (HDACi)PLoS ONE 2013; 8(7): e69992 doi: 10.1371/journal.pone.0069992
16
Qi Xie, Lin Jia, Yan-Hong Liu, Cheng-Gang Wei. Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer <italic>in vivo</italic>World Journal of Gastroenterology 2009; 15(6): 737-741 doi: 10.3748/wjg.15.737
17
Paola Neri, Nizar J Bahlis, Sagar Lonial. Panobinostat for the treatment of multiple myelomaExpert Opinion on Investigational Drugs 2012; 21(5): 733 doi: 10.1517/13543784.2012.668883
18
Shabir Ahmad Ganai. Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy2020; : 173 doi: 10.1007/978-981-15-8179-3_9
19
Jasmijn G.M. van Kampen, Monica A.J. Marijnissen-van Zanten, Femke Simmer, Winette T.A. van der Graaf, Marjolijn J.L. Ligtenberg, Iris D. Nagtegaal. Epigenetic targeting in pancreatic cancerCancer Treatment Reviews 2014; 40(5): 656 doi: 10.1016/j.ctrv.2013.12.002
20
Antonino Grassadonia, Pasquale Cioffi, Felice Simiele, Laura Iezzi, Marinella Zilli, Clara Natoli. Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid MalignanciesCancers 2013; 5(3): 919 doi: 10.3390/cancers5030919
21
Dennis R. Grayson, Marija Kundakovic, Rajiv P. Sharma. Is There a Future for Histone Deacetylase Inhibitors in the Pharmacotherapy of Psychiatric Disorders?Molecular Pharmacology 2010; 77(2): 126 doi: 10.1124/mol.109.061333
22
Joana N.R. Dias, Sandra I. Aguiar, Diane M. Pereira, Ana S. André, Lurdes Gano, João D.G. Correia, Belmira Carrapiço, Barbara Rütgen, Rui Malhó, Conceição Peleteiro, João Goncalves, Cecília M.P. Rodrigues, Solange Gil, Luís Tavares, Frederico Aires-da-Silva. The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphomaOncotarget 2018; 9(47): 28586 doi: 10.18632/oncotarget.25580